These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30171558)

  • 1. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
    Touznik A; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
    Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW; Yokota T
    Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.
    Maruyama R; Touznik A; Yokota T
    J Vis Exp; 2018 May; (135):. PubMed ID: 29806836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review.
    Nakevska Z; Yokota T
    Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
    Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morpholino-Mediated Exon Inclusion for SMA.
    Zhou H; Muntoni F
    Methods Mol Biol; 2018; 1828():467-477. PubMed ID: 30171560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
    Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
    Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
    PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
    Porensky PN; Mitrpant C; McGovern VL; Bevan AK; Foust KD; Kaspar BK; Wilton SD; Burghes AH
    Hum Mol Genet; 2012 Apr; 21(7):1625-38. PubMed ID: 22186025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
    Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
    Hammond SM; Abendroth F; Gait MJ; Wood MJA
    Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.